CRL: Charles River Laboratories International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for CRL
Across the 13 sessions after earlier CRL headlines, the stock closed higher 5 times and lower 8 times, with a median move of 1.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | CRL | SPY |
|---|---|---|---|
| Feb 18, 2026 | Charles River Laboratories Announces Executive Appointmentsand 1 other headline that session | -0.3% | +0.5% |
| Jan 22, 2026 | Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call | -1.2% | +0.5% |
| Jan 21, 2026 | Charles River Enters Manufacturing Collaboration with Gazi University | +3.9% | +1.2% |
| Jan 13, 2026 | Charles River Laboratories Provides Business Updates | +0.1% | -0.2% |
| Jan 8, 2026 | Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan | -0.6% | -0.0% |
| Dec 15, 2025 | Charles River upgraded by BofA Securities with a new price target | +2.7% | -0.2% |
Quantisnow market dataNYSE
CRL
Charles River Laboratories International Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Listed since
- 2000
Get push alerts for CRL
Full CRL profile on Quantisnow Follow CRL and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time